WALTHAM, Mass • 2024-03-12

BostonGene Wins Four GlobalData’s Clinical Trials Arena Excellence Awards

5 min to read

Awards Recognize BostonGene’s Significant Strides to Advance Precision Diagnostics and Improve Patient Outcomes in Innovation, Product Launches and Business Expansion Categories

Waltham, Mass – March 12, 2024 – BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced it has received four Clinical Trials Arena Excellence Awards in the categories of Business Expansion, Innovation and Product Launches. These awards underscore BostonGene’s commitment to advancing personalized therapies and improving outcomes for cancer patients and individuals with immune-related diseases.The Clinical Trials Arena Excellence Awards is an independent recognition program by GlobalData, utilizing researchers, journalists, and artificial intelligence (AI) to analyze over 1 billion datasets yearly. It aims to acknowledge, endorse, and rank top-tier companies and their achievements in over 200 countries. Regarded as one of the industry’s largest and most respected programs, it holds significant value and is the voice of authority.“We extend our congratulations to BostonGene for winning four Clinical Trials Arena Excellence Awards and topping the chart in the Innovation category,” stated Tina Ross, Awards Manager, Clinical Trials Arena Excellence Awards. “BostonGene is transforming precision medicine with their cutting-edge work in molecular diagnostics by improving outcomes for patients, equipping providers with invaluable insights and providing pharmaceutical companies with critical data to accelerate drug development.”“BostonGene is deeply honored to receive these awards from GlobalData,” said Andrew Feinberg, President and CEO of BostonGene. “These awards not only showcase our accomplishments but also our momentum moving forward as we continue to capitalize on our AI-driven diagnostic technologies to facilitate drug development and treatment selection.”In the Innovation category, BostonGene was honored with two awards: one for its groundbreaking Kassandra™ machine learning algorithm for bulk RNA-seq cell type deconvolution and the second award for its proprietary AI-driven clinical trial-matching algorithm. BostonGene was also honored as the Overall Winner in the category.BostonGene’s Product Launches award celebrates the development of a new Liquid Biopsy assay. The CLIA-certified and CAP-accredited test detects clinically actionable gene alterations to predict treatment response and monitor disease progression.The Business Expansion award recognizes BostonGene’s launch of CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling, and Spatial Proteomics solutions, complementing the Tumor Portrait™ next-generation sequencing-based laboratory-developed test. These platforms offer a comprehensive view of each patient’s disease, supporting discovery, translational and clinical efforts in precision oncology.

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin Keleher O'Reilly

Senior Director